Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)

Journal of Cystic Fibrosis

Volumn 13, Issue 6, 2014, Pages 692-698

  Harrison, M J ^a,b   McCarthy, M ^a   Fleming, C ^a   Hickey, C ^a   Shortt, C ^a   Eustace, J A ^b   Murphy, D M ^a,b   Plant, B J ^a,b  

^a University College Cork and INFANT Centre   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; SALBUTAMOL; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICATION COMPLIANCE; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; TREATMENT DURATION; ADOLESCENT; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; NEBULIZER; PATIENT SATISFACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PATIENT SATISFACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUESTIONNAIRES; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911956623     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.04.004     Document Type: Article

References (30)

1. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34(12112774):91-9100.
2. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L., Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001, 32(4):277-287.
3. Courtney J.M., Bradley J., McCaughan J., O'Connor T.M., Shortt C., Bredin C.P., et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007, 42(6):525-532.
4. Simmonds N.J. Ageing in cystic fibrosis and long-term survival. Paediatr Respir Rev 2013, 14(Suppl. 1):6-9.
5. Plant B.J., Goss C.H., Plant W.D., Bell S.C. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 2013, 1(2):164-174.
6. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168(8):918-951.
7. Quittner A.L., Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002, 33(4):269-276.
8. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340(1):23-30.
9. Murphy T.D., Anbar R.D., Lester L.A., Nasr S.Z., Nickerson B., VanDevanter D.R., et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004, 38(4):314-320.
10. Sawicki G.S., Signorovitch J.E., Zhang J., Latremouille-Viau D., von Wartburg M., Wu E.Q., et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012, 47(1):44-52.
11. Geller D.E., Konstan M.W., Smith J., Noonberg S.B., Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007, 42(4):307-313.
12. Sawicki G.S., Sellers D.E., Robinson W.M. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009, 8(2):91-96.
13. Ziaian T., Sawyer M.G., Reynolds K.E., Carbone J.A., Clark J.J., Baghurst P.A., et al. Treatment burden and health-related quality of life of children with diabetes, cystic fibrosis and asthma. J Paediatr Child Health 2006, 42(10):596-600.
14. Quittner A.L., Modi A.C., Lemanek K.L., Ievers-Landis C.E., Rapoff M.A. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol 2008, 33(9):916-936. [discussion 37-8].
15. Modi A.C., Lim C.S., Yu N., Geller D., Wagner M.H., Quittner A.L. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006, 5(3):177-185.
16. Rapoff M.A. Adherence to pediatric medical regimens 1999, Kluwer Academic/Plenum Publishers, New York, NY.
17. Koocher G.P., McGrath M.L., Gudas L.J. Typologies of nonadherence in cystic fibrosis. J Dev Behav Pediatr 1990, 11(6):353-358.
18. Daniels T., Goodacre L., Sutton C., Pollard K., Conway S., Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011, 140(2):425-432.
19. Conway S.P., Pond M.N., Hamnett T., Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996, 51(1):29-33.
20. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011, 10(1):54-61.
21. Schuster A., Haliburn C., Döring G., Goldman M.H. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013, 68(4):344-350.
22. Naehrig S., Lang S., Schiffl H., Huber R., Fischer R. Lung function in adult patients with cystic fibrosis after using the eFlow® rapid for one year. Eur J Med Res 2011, 16(2):63.
23. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2(1):29-34.
24. Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., Oermann C.M., McCoy K.S., Montgomery A.B., et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009, 135(19420195):1223-1232.
25. Littlewood J.M., Miller M.G., Ghoneim A.T., Ramsden C.H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985, 1(8433):865.
26. Briesacher B.A., Quittner A.L., Saiman L., Sacco P., Fouayzi H., Quittell L.M. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011, 11:5.
27. de Boer K., Vandemheen K.L., Tullis E., Doucette S., Fergusson D., Freitag A., et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011, 66(8):680-685.
28. Parkins M.D., Rendall J.C., Elborn J.S. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012, 141(2):485-493.
29. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182(5):627-632.
30. Newhouse M.T., Hirst P.H., Duddu S.P., Walter Y.H., Tarara T.E., Clark A.R., et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003, 124(1):360-366.